Isomorphic Labs Completes $5 Billion Series C Funding
Isomorphic Labs, an AI drug discovery company founded by DeepMind co-founder Hassabis, has announced the completion of a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with Alphabet continuing to invest heavily. Together with its earlier $600 million first external financing and $2.1 billion Series B, the company's publicly disclosed funding totals $7.7 billion. The new funds will be used to upgrade its drug design engine IsoDDE, expand its in-house and partnered drug candidate pipelines, and build global AI-driven bioengineering infrastructure; its internal oncology and immunology programs and partnered projects have achieved positive preclinical results and are preparing to enter clinical trials.
Why read this
AI score 60
Isomorphic Labs has raised a cumulative total of $7.7 billion, with the use of funds extending from model R&D to drug pipelines and clinical development, allowing readers to observe the pace at which AI pharma is being implemented.
Topics
Body · AI translation
Just now, the AI company of a Nobel laureate raised 33.3 billion yuan. Zhi Dongxi Download the client for exclusive early access. November 17, 2026, 21:44:01 From Beijing
Zhi Dongxi news on November 17: Just now, the UK AI drug discovery company Isomorphic Labs, founded by Nobel laureate and Google DeepMind co-founder Demis Hassabis, announced the completion of a $5 billion (approximately 33.3 billion yuan) Series C funding round, which was oversubscribed.
▲Hassabis announces that Isomorphic Labs has completed its Series C funding round (Image source: X)
In March 2025, Isomorphic Labs announced the completion of a $600 million (approximately 4 billion yuan) first external funding round. In May of this year, the company secured another $2.1 billion (approximately 14 billion yuan) Series B funding round, setting a new record at the time for a single funding round in the global AI pharmaceutical industry. Including this Series C round, the total publicly disclosed funding for Isomorphic Labs amounts to $7.7 billion (approximately 51.3 billion yuan).
This round was co-led by Greenoaks and Sequoia Capital, with participation from a16z and several new investors, while Alphabet continued to invest heavily. All existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, also participated in this round.
Isomorphic Labs was founded in 2021 and is headquartered in London, UK. It focuses on using AI to design and develop new drugs. The company plans to use the new funds to upgrade its proprietary drug design engine IsoDDE, expand its internal and partnered drug candidate pipelines, and build global AI-driven bioengineering infrastructure. The company says its internal oncology and immunology programs and partnered programs have achieved positive preclinical results and are preparing to enter clinical trials.
1. Founded by a Google DeepMind co-founder, focused on AI drug design
Isomorphic Labs was incubated and established by Google DeepMind. It is an AI drug discovery company under Alphabet, Google's parent company, and operates independently with external funding. The company is led by founder and CEO Demis Hassabis and President Max Jaderberg.
Hassabis is a co-founder and chairman of Google DeepMind and Chief Scientist of Alphabet. He won the 2024 Nobel Prize in Chemistry for his research on AlphaFold in protein structure prediction.
▲Isomorphic Labs founder and CEO Hassabis
Jaderberg holds a doctorate from the University of Oxford and previously led DeepMind's open-ended learning research team. He is a founding team member of Isomorphic Labs, previously served as Chief AI Officer, led the development of the company's drug design engine and models such as AlphaFold 3, and became the company's President in January 2026.
Hassabis said that when Isomorphic Labs was founded, the team believed that biology could be understood and modeled at the most fundamental molecular level, and that AI could significantly accelerate this process.
He also said that Isomorphic Labs' drug design engine is generating molecules with greater precision and speed, and that this funding round will help the team advance its work faster: building foundational biology models, deepening understanding of systemic disease mechanisms, and moving the first therapeutic programs toward clinical trials.
Isomorphic Labs' core technology is its proprietary drug design engine IsoDDE. The engine integrates a set of foundational simulation AI models and can cover multiple therapeutic areas and different drug modalities.
IsoDDE can explore vast chemical space and help R&D teams design, optimize and screen molecules with desirable drug-like properties. Isomorphic Labs says these simulation models are pushing predictions close to experimental accuracy, providing more capabilities for innovative drug discovery.
In addition to simulation models, Isomorphic Labs has also developed proprietary agents for exploring complex biological systems and performing reasoning. The company says that combining its models and agents has continued to drive progress across multiple types of drug candidate pipelines. At present, the company's internal oncology and immunology programs and partnered programs have achieved positive preclinical results, laying the foundation for entering the clinical stage.
Isomorphic Labs President Jaderberg said the team can use the models every week to achieve reproducible scientific progress and translate it into better molecular properties, and these molecules have the potential to be further developed into new drugs. The company's interdisciplinary team brings together machine learning researchers and drug discovery researchers and is trying to solve complex biological problems that have been stalled for decades.
After this funding round, Isomorphic Labs will continue to improve IsoDDE and use more advanced models to explore new areas of biology.
The company also plans to build a partner ecosystem and deepen understanding of disease mechanisms to support the development of new therapeutic drug classes. At the same time, Isomorphic Labs will build global bioengineering infrastructure and a scalable, AI-centered translational research and clinical development system to support drug candidates entering clinical trials.
Conclusion: After the massive funding round, clinical validation becomes key
The use of this funding has expanded from model research and development to drug pipelines, translational research and clinical development infrastructure. For Isomorphic Labs, how to translate computational prediction and molecular design capabilities into drug candidates that can enter clinical trials is an important task for the next stage.
At present, most of Isomorphic Labs' main achievements are still in the preclinical stage. As the first batch of programs advances toward clinical trials, the safety, efficacy and development progress of its drug candidates will become important evidence for testing AI drug design capabilities.
Source: Isomorphic Labs, X
"Special statement: The above content (including videos, pictures or audio if any) is uploaded and published by users of 'Dafeng Hao', a self-media platform under Phoenix Net. This platform only provides information storage space services.
Notice: The content above (including the videos, pictures and audios if any) is uploaded and posted by the user of Dafeng Hao, which is a social media platform and merely provides information storage space services."
AI Trends